Takeover

ABUSArbutus Biopharma Corp

Pharmaceutical Preparations

Revenue
$14MFY2021: $11MFY2022: $39MFY2023: $18MFY2024: $6MFY2025: $14M
128% YoY
Operating margin
-271.0%FY2021: -669.1%FY2022: -167.8%FY2023: -430.5%FY2024: -1236.7%FY2025: -271.0%
78% YoY
EBITDA
−$38MFY2021: −$72MFY2022: −$64MFY2023: −$77MFY2024: −$75MFY2025: −$38M
50% YoY
Market cap
$832M
Employees
—
Net debt / EBITDA
—
−$19M net debt
AI in 10-K
1.4
mentions per 10K words

Takeover score 3 of 13

Fixable underperformance 1 of 7

Buyer economics 1 of 4

Catalysts 1 of 2

Financials

MetricFY2021FY2022FY2023FY2024FY2025YoYTrend
Revenue$11M$39M$18M$6M$14M 128% FY2021: $11MFY2022: $39MFY2023: $18MFY2024: $6MFY2025: $14M
Operating income−$74M−$65M−$78M−$76M−$38M 50% FY2021: −$74MFY2022: −$65MFY2023: −$78MFY2024: −$76MFY2025: −$38M
Net income−$76M−$69M−$73M−$70M−$34M 52% FY2021: −$76MFY2022: −$69MFY2023: −$73MFY2024: −$70MFY2025: −$34M
Operating cash flow−$68M−$35M−$86M−$65M−$40M 39% FY2021: −$68MFY2022: −$35MFY2023: −$86MFY2024: −$65MFY2025: −$40M
Capex$809K$512K$1M$182K$0 100% FY2021: $809KFY2022: $512KFY2023: $1MFY2024: $182KFY2025: $0
Stock-based comp$6M$7M$9M$9M$7M 23% FY2021: $6MFY2022: $7MFY2023: $9MFY2024: $9MFY2025: $7M

Deal filings

FiledFormAcquirerPricePremium
Feb 4, 2015DEFM14AOnCore Biopharma, Inc.——
Jan 23, 2015PREM14ATekmira Pharmaceuticals Corporation$23.6633.33%

13D filers

FiledFilerFormStakeIntent
Oct 5, 2026Roivant Sciences Ltd.SCHEDULE 13D/A19.5%Passive
Apr 28, 2026Whitefort Capital Management, LPSCHEDULE 13D/A8.0%Passive
Apr 13, 2026Whitefort Capital Management, LPSCHEDULE 13D/A8.1%Active
Feb 25, 2025Roivant Sciences Ltd.SCHEDULE 13D/A20.5%Active
Feb 21, 2025Whitefort Capital Management, LPSCHEDULE 13D/A7.0%Active
Feb 18, 2025Roivant Sciences Ltd.SCHEDULE 13D/A20.5%Active
May 17, 2024Whitefort Capital Management, LPSC 13D/A6.8%Active
May 9, 2024Whitefort Capital Management, LPSC 13D6.8%Active
Oct 20, 2021Roivant Sciences Ltd.SC 13D/A29.1%Passive
Jul 17, 2019Lo AndrewSC 13D/A0.0%Passive

Insider trading

No open-market trades in the last 12 months.

Pay vs performance

YearCEO total compComp actually paidTSR (indexed)Peer TSR
FY2025——206—
FY2024——140—
FY2023——107—